Manchester, UK, August 2008 - F2G Limited, the Manchester UK based antifungal
drug discovery and development company, today announced the completion of a 6.3
million equity financing round with an international syndicate of investors.
The funding will be used, in part, to support the development of F2G’s novel antifungal
lead compound which is currently in pre-clinical development. FG3622 is a potent,
novel, small molecule antifungal, active against a wide range of clinically significant
moulds. In addition it has a new Mechanism of Action for systemic antifungal agents.
F2G Ltd is dedicated to the discovery and development of new and clinically superior
drug classes to treat life-threatening systemic fungal infections in at-risk patient
populations. The antifungal market is currently estimated at over five and a half billion
dollars annually and is growing steadily year on year. Market growth is expected to
increase with the emergence of new clinical indications in allergies and asthma.
The funding, led by BankInvest Biomedical Venture (Denmark), will allow F2G to
accelerate the development of FG3622 and other novel antifungal agents. Merifin
Capital, Astellas Venture Management and K Nominees also participated in the
Mr Shane Kelly, CEO of F2G Ltd, said: “This financing is a strong endorsement of the
outstanding work performed by the F2G team. We are delighted with the continued
support from our investors and the current funding represents complete validation of our
lead program and other ongoing projects. The resources will allow the Company to
push through the development of FG3622 and other interesting programs.”
Mr Jens Kindtler, Partner at BankInvest Biomedical Venture and Chairman of the F2G
Board of Directors, commented: “We are delighted to continue our support of F2G.
FG3622 is an exciting, novel molecule that will impact heavily on the current antifungal
market. There is significant clinical need for a new systemic agent and FG3622 has the
potential to fulfil this gap.”
Shane M. Kelly
Chief Executive Officer
Tel: (+44) 0161 785 1271
Fax: (+44) 0161 785 1273